Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

Blakey, G E; Lockton, J A; Perrett, J; Norwood, P; Russell, M; Aherne, Z; Plume, J

Blakey, G E; Lockton, J A; Perrett, J; Norwood, P; Russell, M; Aherne, Z; Plume, J.

Affiliation

Blakey GE; Department of Experimental Medicine, AstraZeneca R & D, Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, UK. graham.blakey@astrazeneca.com

Br J Clin Pharmacol ; 57(2): 162-9, 2004 Feb.

Article in En | MEDLINE | ID: mdl-14748815

Subject(s)

Caffeine/pharmacology; Chlorzoxazone/pharmacology; Cytochrome P-450 Enzyme System/drug effects; Debrisoquin/pharmacology; Midazolam/pharmacology; Tolbutamide/pharmacology; Adult; Caffeine/blood; Caffeine/pharmacokinetics; Chlorzoxazone/blood; Chlorzoxazone/pharmacokinetics; Debrisoquin/blood; Debrisoquin/pharmacokinetics; Drug Combinations; Drug Interactions; Female; Humans; Male; Midazolam/blood; Midazolam/pharmacokinetics; Middle Aged; Plasma; Tolbutamide/pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tolbutamide / Midazolam / Caffeine / Chlorzoxazone / Cytochrome P-450 Enzyme System / Debrisoquin Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2004 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google